We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Vifor Pharma's Phase III study on its ...

olaparib targets prostate cancer mutations Calcium-based binders, however, are associated with greater odds of all-cause mortality versus sevelamer. Phosphate-binder therapy does not reduce mortality ...